Adoptive T cell immunotherapy for treatment of ganciclovir‐resistant cytomegalovirus disease in a renal transplant recipient
N Macesic, D Langsford, K Nicholls… - American Journal of …, 2015 - Wiley Online Library
American Journal of Transplantation, 2015•Wiley Online Library
Cytomegalovirus (CMV) is a significant cause of morbidity, mortality and graft loss in solid
organ transplantation (SOT). Treatment options for ganciclovir‐resistant CMV are limited. We
describe a case of ganciclovir‐resistant CMV disease in a renal transplant recipient
manifested by thrombotic microangiopathy‐associated glomerulopathy. Adoptive T cell
immunotherapy using CMV‐specific T cells from a donor bank was used as salvage therapy.
This report is a proof‐of‐concept of the clinical and logistical feasibility of this therapy in SOT …
organ transplantation (SOT). Treatment options for ganciclovir‐resistant CMV are limited. We
describe a case of ganciclovir‐resistant CMV disease in a renal transplant recipient
manifested by thrombotic microangiopathy‐associated glomerulopathy. Adoptive T cell
immunotherapy using CMV‐specific T cells from a donor bank was used as salvage therapy.
This report is a proof‐of‐concept of the clinical and logistical feasibility of this therapy in SOT …
Cytomegalovirus (CMV) is a significant cause of morbidity, mortality and graft loss in solid organ transplantation (SOT). Treatment options for ganciclovir‐resistant CMV are limited. We describe a case of ganciclovir‐resistant CMV disease in a renal transplant recipient manifested by thrombotic microangiopathy‐associated glomerulopathy. Adoptive T cell immunotherapy using CMV‐specific T cells from a donor bank was used as salvage therapy. This report is a proof‐of‐concept of the clinical and logistical feasibility of this therapy in SOT recipients.
Wiley Online Library